Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Brodalumab (KHK4827) in Plaque Psoriasis
NCT01782924Phase 3Completed
- Sponsor
- Kyowa Kirin
- Start
- Mar 2013
- Primary completion
- Feb 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label trial of brodalumab in plaque psoriasis (2 arms), sponsored by Kyowa Kirin. Primary endpoints: Incidence and types of adverse events and adverse reactions at 52 weeks, Laboratory values and vital signs at 52 weeks and 1 more. Started Mar 2013; status: completed.
02
Drugs
brodalumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT01782924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01782924.